Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
NCT05691400 · University of Michigan Rogel Cancer Center · PHASE4 · withdrawn · last registry update 2024-02-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “funding was not secured” | – | Registry record, University of Michigan Rogel Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CCND1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-07Phase 3 first posted: Pfizer, PF-07220060 + letrozole (NCT06760637)
- 2025-01-03Phase 3 first posted: Celcuity Inc, Arm A: Gedatolisib + Palbociclib + Fulvestrant + Arm B: Ribociclib + Fulvestrant (NCT06757634)
- 2024-12-27Results posted on the registry: M.D. Anderson Cancer Center, Abemaciclib + Anastrozole (NCT04256941)
- 2024-12-27Also stopped (terminated): M.D. Anderson Cancer Center, Abemaciclib + Anastrozole (NCT04256941)
- 2024-12-13Results posted on the registry: ETOP IBCSG Partners Foundation, Paclitaxel + Trastuzumab (NCT03644186)
- 2024-12-10Results posted on the registry: National Cancer Institute (NCI), Palbociclib (NCT06390839)
- 2024-12-09Results posted on the registry: MedSIR, Palbociclib + Fulvestrant (NCT02491983)
- 2024-11-22Results posted on the registry: Grupo Español de Investigación en Neurooncología, Palbociclib (NCT02530320)
- 2024-11-22Results posted on the registry: Pfizer, a drug against CCND1 (NCT04736576)
- 2024-11-08Results posted on the registry: Hoffmann-La Roche, Ipatasertib + Placebo (NCT04060862)
- 2024-11-08Also stopped (terminated): Hoffmann-La Roche, Ipatasertib + Placebo (NCT04060862)
- 2024-10-09Results posted on the registry: Hoffmann-La Roche, Inavolisib + Placebo (NCT04191499)
- 2024-09-25Results posted on the registry: Spanish Breast Cancer Research Group, Palbociclib + Capecitabine (NCT02028507)
- 2024-09-23Results posted on the registry: Shannon Puhalla, Fulvestrant + Tamoxifen (NCT02913430)
- 2024-09-19Also stopped (withdrawn): Brown University, Palbociclib Oral Product + TAS-116 (NCT05655598)
- 2024-09-03Results posted on the registry: Pfizer, PF-06804103 + PF-06804103 + Palbociclib +Letrozole (NCT03284723)
- 2024-09-03Also stopped (terminated): Pfizer, PF-06804103 + PF-06804103 + Palbociclib +Letrozole (NCT03284723)
- 2024-08-19Also stopped (suspended): Ascentage Pharma Group Inc., APG-2575 + Palbociclib (NCT04946864)
- 2024-08-16Results posted on the registry: Children's Oncology Group, Palbociclib + Cytarabine (NCT03792256)
- 2024-08-14Results posted on the registry: Jazz Pharmaceuticals, ZW25 (Zanidatamab) + Palbociclib (NCT04224272)
- 2024-08-09Results posted on the registry: Zeno Alpha Inc., ZN-c5 + Palbociclib (NCT03560531)
- 2024-08-07Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Cetuximab + Palbociclib (NCT03446157)
- 2024-08-01Also stopped (terminated): Dana-Farber Cancer Institute, Palbociclib + Ganitumab (NCT04129151)
- 2024-07-29Results posted on the registry: Oana Danciu, MD, Palbociclib + Tamoxifen (NCT02668666)
- 2024-07-24Results posted on the registry: University of Arizona, Palbociclib + T-DM1 (NCT03530696)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision